Obinutuzumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1280 publications

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 28, 2026

B-cell depletion therapy in systemic lupus erythematosus: emerging strategies and challenges.

B-cell depletion therapy in systemic lupus erythematosus: emerging strategies and challenges.

Journal: Expert opinion on biological therapy

Published: August 28, 2026

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 27, 2026

Efficacy and safety of obinutuzumab in children with refractory nephrotic syndrome

Efficacy and safety of obinutuzumab in children with refractory nephrotic syndrome

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: August 17, 2026

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 14, 2026

Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.

Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.

Journal: Journal of internal medicine

Published: August 05, 2026

Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report

Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Which patients should switch from rituximab to obinutuzumab in refractory nephrotic syndrome?

Which patients should switch from rituximab to obinutuzumab in refractory nephrotic syndrome?

Journal: Pediatric nephrology (Berlin, Germany)

Published: July 31, 2026

Optimizing Administration of Obinutuzumab: A Strategy to Minimize Infusion-Related Reactions.

Optimizing Administration of Obinutuzumab: A Strategy to Minimize Infusion-Related Reactions.

Journal: Journal of investigational allergology & clinical immunology

Published: July 29, 2026

Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.

Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.

Journal: Immunotherapy

Published: July 18, 2026

Correction: Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study.

Correction: Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study.

Journal: Journal of pharmaceutical health care and sciences

Published: July 18, 2026

Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy.

Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy.

Journal: Lupus

Published: July 09, 2026

Showing 1-12 of 1,280

Last Updated: 09/26/2026